No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
zanubrutinib
BeiGene Press Release - 5 days
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
PCR
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
FCR
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
alemtuzumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
rituximab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
obinutuzumab
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
zanubrutinib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
zanubrutinib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
rituximab + idelalisib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
rituximab
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
rituximab
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
ibrutinib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
ibrutinib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
ofatumumab
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
ofatumumab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
idelalisib
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
idelalisib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
venetoclax
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
venetoclax
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
rituximab + idelalisib
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
rituximab + idelalisib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
duvelisib
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
duvelisib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
venetoclax + rituximab
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
venetoclax + rituximab
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
obinutuzumab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
obinutuzumab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
alemtuzumab
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
alemtuzumab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
rituximab + alemtuzumab
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
rituximab + alemtuzumab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
venetoclax + obinutuzumab
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
venetoclax + obinutuzumab
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
acalabrutinib
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
acalabrutinib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
chlorambucil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
venetoclax + obinutuzumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
ibrutinib + obinutuzumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
CD20 inhibitor
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
lenalidomide
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
rituximab + lenalidomide
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
lenalidomide
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
rituximab + lenalidomide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
ofatumumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
lenalidomide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
rituximab + lenalidomide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
rituximab + alemtuzumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
rituximab + idelalisib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
duvelisib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
venetoclax + rituximab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
obinutuzumab + acalabrutinib
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
pembrolizumab + ibrutinib
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
pembrolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
OFAR
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
R-CVAD
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
EPOCH-R
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
R-CHOP
Sensitive: A2 - Guideline
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
pembrolizumab + ibrutinib
Sensitive: A2 - Guideline
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
pembrolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
BR
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
BR + ibrutinib
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
BR + idelalisib
Sensitive: A2 - Guideline
|
TP53 deletion
TP53 deletion
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
ibrutinib
Sensitive: A2 - Guideline
|
BIRC3 mutation
BIRC3 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
ibrutinib
Sensitive: B - Late Trials
|
IGH mutation
IGH mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
ibrutinib
Sensitive: B - Late Trials
|
Chr del(11q)
Chr del(11q)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
ibrutinib
Sensitive: B - Late Trials
|
Chr del(11q)
Chr del(11q)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
zanubrutinib
Sensitive: B - Late Trials
|
TP53 mutation + Chr del(17p)
TP53 mutation + Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
LOXO-305
Sensitive: C3 – Early Trials
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
LOXO-305
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
LOXO-305
Sensitive: C3 – Early Trials
|
TP53 mutation + Chr del(17p)
TP53 mutation + Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
ICP-022
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
ICP-022
Sensitive: C3 – Early Trials
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
ICP-022
Sensitive: C3 – Early Trials
|
Chr del(11q)
Chr del(11q)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
ICP-022
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
obinutuzumab + zanubrutinib
Sensitive: C3 – Early Trials
|
IGH mutation
IGH mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
FCR
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
FCR
Sensitive: C3 – Early Trials
|
Chr del(17)(p13.1)
Chr del(17)(p13.1)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
acalabrutinib
Sensitive: C3 – Early Trials
|
Chr del(11)(q22.3)
Chr del(11)(q22.3)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
acalabrutinib
Sensitive: C3 – Early Trials
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
venetoclax + ibrutinib
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
venetoclax + ibrutinib
Sensitive: C3 – Early Trials
|
Chr del(17p)
Chr del(17p)
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
ibrutinib + lisocabtagene maraleucel
Sensitive: C3 – Early Trials
|
TP53 mutation
TP53 mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
ibrutinib + lisocabtagene maraleucel
Sensitive: C3 – Early Trials
|
ATM mutation
ATM mutation
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
T-lymphocyte cell therapy
Sensitive: C4 – Case Studies
|
CD19 positive
CD19 positive
|
Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
|
T-lymphocyte cell therapy
Sensitive: C4 – Case Studies
|
